FANJ
CLDX icon

Financial Architects (New Jersey)’s Celldex Therapeutics CLDX Stock Holding History

Financial Architects (New Jersey)’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13
Closed -$1K – 1498
2017
Q3 		$1K Buy
+13
New +$487 ﹤0.01% 1445

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Financial Architects (New Jersey)'s CLDX Position: Q2 2019 in Review

Financial Architects (New Jersey) sold out of Celldex Therapeutics (CLDX) in Q2 2019, closing a stake of 149 shares — an estimated $1K sold.

Financial Architects (New Jersey) first reported a position in CLDX in Q2 2016 and held it in 12 quarters. The position peaked at $10K in Q4 2017. 51 funds tracked by Wall St. Rank hold CLDX as of Q2 2019.

  • Financial Architects (New Jersey) reported no remaining Celldex Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 149 Celldex Therapeutics shares in Q2 2019, an estimated $1K.
  • Financial Architects (New Jersey) first reported a position in Celldex Therapeutics in Q2 2016 and held it in 12 quarters.
  • Financial Architects (New Jersey)'s Celldex Therapeutics position peaked at $10K in Q4 2017.
  • 51 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2019.

Based on Financial Architects (New Jersey)'s 13F filing for Q2 2019, filed 14 Aug 2019.